Dr. Smith's research focuses on the economic evaluation of medical interventions and pharmacoepidemiology. He is site principal investigator for the HMO CERTS (Centers for Research & Education on Therapeutics), an AHRQ-funded collaboration of HMOs focusing on pharmacy issues. Dr. Smith is involved in studies analyzing prescribing behavior, medication adherence, drug use and outcomes, and FDA-funded studies on drug safety.

Dr. Smith is conducting other pharmacy related research involving patient safety, including methods to reduce errors through alerting systems in automated physician prescribing. He is currently leading several industry-funded studies on the natural history of chronic kidney disease. He is also leading an Robert Wood Johnson-funded investigation into financial incentives in the treatment of depression in the primary care setting.

Dr. Smith received his pharmacy degree from the University of Washington in 1990. After completing his residency in General/Clinical Pharmacy he worked as a clinical pharmacist in home care. He received an MHA in Health Services Administration in 1995, and was awarded a PhD in Pharmacy Outcomes Research from the University of Washington in 1998. He is an Honorary Visiting Fellow at the University of York, Centre for Health Economics, and is adjunct assistant professor at the University of Washington's School of Pharmacy.

Current Studies:

	An Assessment of the Natural History of Chronic Kidney Disease
	Cardiovascular Outcomes in Adults (CERT ADHD Phase II)
	Centers for Education and Research on Therapeutics
	CERT Epidemiological Studies of the Adverse Events of Marketed Drugs
	Developing prognostic risk scores to predict adverse events among patients starting angiotensin converting enzyme inhibitors
	Diabetes and Drug-Associated Hyperkalemia: Effect of Laboratory Monitoring—HyperK
	Evidence-Based Laboratory Medicine: Quality/Performance Evaluation in CKD—CKD LAB
	Evidence-based Practice Center—U.S. Preventive Services Task Force
	HMO Research Network Cardiovascular Research Network—CVRN
	Kaiser Permanente Northwest's Patients with Heart Failure: Predicting Mortality, Healthcare Costs and Cardiovascular Hospitalization
	Lotronex
	Patients with Chronic Kidney Disease and End-Stage Renal Disease: Predicting Clinical Outcomes, Healthcare Utilization, and Direct Medical Costs in Relation to Anemia Management and Calcium and Phosphorous Management
	Patients with Chronic Kidney Disease: Developing a Risk Equation to Predict Mortality and Progression to End-Stage Renal Disease

Recently Completed Studies:

	Centers for Education and Research on Therapeutics—CERTS
	Does Equity Matter in Managed Care
	Excess Rate of All-Cause Mortality Among Patients with Chronic Kidney Disease and Elevated Serum Phosphate
	Excess Rates of Healthcare Utilization Among Patients with Elevated Parathyroid Values
	Factors Associated with Gaps in Osteoporosis Treatment—Factors
	Financial Incentives in Depression — FIND
	Incidence of Drug-Induced Liver Injury—Chan Liver
	Naturalistic Pharmacotherapy for Youth Depression — LEAP
	Population-based HMO Study of Gout Pharmacoepidemiology-GOUT
	Prevalence of and Strategies for Appropriate Prescription Medication Dosing for Children – Kids Meds
	Re-Fracture Intervention Trial — REFIT
	The Community-Based Rates of Psychiatric Events, Suicide-Related Events, Convulsions and Cardiovasular Events According to Patients' Body Mass Index: A Retrospective Cohort Study — BIRO
	The Epidemiology and Natural History of Food Allergies
	The Refracture Intervention Trial Phase 2—REFIT 2
	Weight in Secondary Prevention — WISP

E-mail: David.H.Smith@kpchr.org